Clinical trial
A Double-Blind, Placebo-Controlled, Double-Dummy Study of Donanemab and RG6289 in PSEN1 E280A Mutation Carriers, and in Non-Randomized, Placebo-Treated Non-Carriers From the Same Kindred, to Evaluate the Efficacy and Safety of Donanemab, RG6289, or the Combination of Donanemab and RG6289, in the Treatment of Autosomal-Dominant Alzheimer's Disease
NCT06996730 is registered in ClinicalTrials.gov with Banner Health as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-Blind, Placebo-Controlled, Double-Dummy Study of Donanemab and RG6289 in PSEN1 E280A Mutation Carriers, and in Non-Randomized, Placebo-Treated Non-Carriers From the Same Kindred, to Evaluate the Efficacy and Safety of Donanemab, RG6289, or the Combination of Donanemab and RG6289, in the Treatment of Autosomal-Dominant Alzheimer's Disease
- Lead sponsor
- Banner Health
- Phase
- Phase 2/3
- Overall status
- Recruiting
- Start date
- July 8, 2026
- Completion date
- June 1, 2030
- Enrollment
- 240 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
alzheimers disease, autosomal dominant alzheimers disease, early onset alzheimer disease